Pubblicazioni

Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?  (2021)

Autori:
Cuzzolin, Laura; Oggiano, Anna Maria; Clemente, Maria Grazia; Locci, Cristian; Antonucci, Luca; Antonucci, Roberto
Titolo:
Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?
Anno:
2021
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Formato:
Elettronico
Referee:
No
Nome rivista:
FUNDAMENTAL & CLINICAL PHARMACOLOGY
ISSN Rivista:
0767-3981
N° Volume:
35
Numero o Fascicolo:
1
Editore:
BLACKWELL PUBLISHING LTD
Intervallo pagine:
40-52
Parole chiave:
biliary sludge; ceftriaxone; children; cholelithiasis; gallstones
Breve descrizione dei contenuti:
Ceftriaxone is an antibiotic agent frequently used in paediatric hospital practice for the treatment of severe bacterial infections. The use of this agent can result in cholelithiasis and/or biliary sludge, more commonly in children than in adults. This systematic review was aimed at analysing available literature concerning ceftriaxone-associated biliary pseudolithiasis in paediatric patients, with a special emphasis on the clinical aspects. A literature analysis was performed using Medline and Embase electronic databases (articles published in English up to December 2019), with the search terms and combinations as follows:'ceftriaxone', 'cholelithiasis', 'biliary sludge' 'gallstones' 'neonates' 'children' 'clinical aspects' 'management'. Several case reports, case series and prospective/retrospective studies have documented a relationship between ceftriaxone treatment and biliary pseudolithiasis in the paediatric population, even though literature data regarding neonates and infants are scarce. Ceftriaxone-associated biliary pseudolithiasis is dose-dependent and usually asymptomatic but, sometimes, it may present with abdominal pain, nausea and emesis. Abdominal ultrasonography should be performed when this complication is suspected. Generally, ceftriaxone-associated cholelithiasis resolves over a variable period of time (days to months) after cessation of therapy. Therefore, a conservative approach to this condition is advocated, but a prolonged follow-up may be necessary. A personalized assessment of factors predisposing to ceftriaxone-associated biliary pseudolithiasis before prescribing the drug can allow to minimize the risk of developing it, with significant advantages in terms of human and economic costs.
Id prodotto:
118545
Handle IRIS:
11562/1032648
ultima modifica:
15 novembre 2022
Citazione bibliografica:
Cuzzolin, Laura; Oggiano, Anna Maria; Clemente, Maria Grazia; Locci, Cristian; Antonucci, Luca; Antonucci, Roberto, Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough? «FUNDAMENTAL & CLINICAL PHARMACOLOGY» , vol. 35 , n. 12021pp. 40-52

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro

Attività

Strutture

Condividi